Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017 (GESIDA10017)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03626467
Recruitment Status : Active, not recruiting
First Posted : August 13, 2018
Last Update Posted : February 5, 2020
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Fundacion SEIMC-GESIDA

Brief Summary:
Phase IV, open, multicenter and single-arm clinical trial designed to evaluate the immunogenicity of the HPV9v vaccine in men with HIV infection (HIV +) who have sex with men (MSM)

Condition or disease Intervention/treatment Phase
HIV Infections Biological: HPV9v Phase 4

Detailed Description:
The investigators estimate that 166 participants will need to be included in the study to evaluate the immunogenicity of vaccine against human papillomavirus in men with HIV infection who have sex with men, by evaluating in two age groups and the seroconversion rate for each of the HPV genotypes included in the vaccine from baseline to month 7 and 24.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 158 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: A phase IV, open-label and single-arm clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Open-label, Multicenter and Single-arm on the Immunogenicity of Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
Actual Study Start Date : October 15, 2018
Estimated Primary Completion Date : December 15, 2020
Estimated Study Completion Date : December 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Arm 1
Men infected by HIV who have sex with men
Biological: HPV9v
Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
Other Name: Gardasil9




Primary Outcome Measures :
  1. Percentage of subjects who serocovertize for each of the HPV genotypes included in the vaccine [ Time Frame: From basal until week 96 ]
    The HPV genotypes studied are: 6/11/16/18/31/33/45/52/58. The cut-off points to determine serological status 30, 16, 20, 24, 10, 8, 8, 8, and 8 units / mL for HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52 , and 58, respectively


Secondary Outcome Measures :
  1. Number of participants with low CD4 / CD8 ratio (<0.5) and normal ratio (> 1) [ Time Frame: From basal until week 96 ]
    The low CD4 / CD8 ratio has been associated with immunosenescence in the serological response, such as worse immunogenicity and worse response to vaccines

  2. Number and type of metabolites derived from the microbiota of patients [ Time Frame: From basal until week 96 ]
    Detect biomarkers derived from microbiota and their relationship with the vaccine response

  3. Percentage of participants <26 years and ≥ 26 years with persistent anal infection due to HPV [ Time Frame: Basal, week 28 and week 96 ]
  4. The proportion of subjects experiencing adverse events [ Time Frame: From basal until week 96 ]
    Adverse events

  5. The proportion of subjects with a severe adverse experience [ Time Frame: From basal until week 96 ]
    Adverse events

  6. The proportion of subjects with an adverse experience leading to disruption [ Time Frame: From basal until week 96 ]
    Adverse events

  7. The proportion of subjects with an adverse experience related to medication [ Time Frame: From basal until week 96 ]
    Adverse events

  8. The proportion of subjects experiencing adverse events related to laboratory values at any time during the study period [ Time Frame: From basal until week 96 ]
    Adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients able to give their written consent to participate in the study. (preferably in writing or, failing that, orally before independent witnesses of the research team) after having received information about the design, the purposes of the study, the possible risks that may arise from it and the possibility of withdrawing from it at any time. moment.
  • Understand the purpose of the study and be available to perform the visits stipulated in the protocol.
  • Be ≥18 years and <of 36 years.
  • Patient with chronic infection with HIV-1.
  • Viral HIV load <50 copies / ml and CD4> 200 cells / uL for at least the last six months.
  • Transgender men or women who have had insertive or receptive anal sex with other men

Exclusion Criteria:

  • Previous history of anal cancer.
  • Have previously received any vaccine against HPV.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03626467


Locations
Layout table for location information
Spain
Hospital Ramón y Cajal
Madrid, Spain, 28034
Hospital Fundación Jimenez Díaz
Madrid, Spain
Hospital La Paz
Madrid, Spain
Sponsors and Collaborators
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: Fundacion SEIMC-GESIDA
ClinicalTrials.gov Identifier: NCT03626467    
Other Study ID Numbers: GESIDA10017
First Posted: August 13, 2018    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases